ClinicalTrials.gg
CompletedNCT03291041Updated Nov 3, 2021Results posted

A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder

A Phase 2 interventional study of Tasimelteon and Placebo in Jet Lag Disorder, sponsored by Vanda Pharmaceuticals. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-03.

Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder

02

Conditions studied

  • Jet Lag Disorder
03

In context

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability and acceptance to provide written consent
  • Men or women between 18-75 years
  • of ≥ 18 and ≤ 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • History (within the 12 months prior to screening) of psychiatric disorders
  • Major surgery, trauma, illness or immobile for 3 or more days within the past month
  • Pregnancy or recent pregnancy (within 6 weeks)
  • A positive test for drugs of abuse at the screening visit
  • Any other sound medical reason as determined by the clinical investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    tasimelteon

    tasimelteon, administered as oral capsule(s)

    Drug: Tasimelteon

  • Placebo comparator
    Placebo

    Placebo, administered as oral capsule(s)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Total Sleep Time in the First Two-Thirds of the Night on the Night(s) Most Likely to be Disrupted

    Measured using polysomnography (PSG) and analyzed as change from baseline. Examination of the observational phase baseline data demonstrated that Night 3 was the night most disrupted.

    Time frame: 4 days

Secondary outcomes

  1. Patient Global Impression of Severity (PGI-S) Day 4

    Self-reported global index measure analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight. The PGI-S is a single question asking the subject to rate their jet-lag condition at the present time on a scale of 1 "Normal" to 4 "Severe".

    Time frame: 1 Day

  2. Total Sleep Time in the First Two-Thirds of the Night (All 3 Nights)

    Measured using polysomnography (PSG) and analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight.

    Time frame: 3 Days

  3. Subjective Total Sleep Time on Night 3

    Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline

    Time frame: 1 Day

  4. Subjective Sleep Quality Night 3

    Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline. Sleep quality was ranked from 1 "Poor" to 5 "Excellent" and was the subscale of the post-sleep questionnaire used to determine subjective sleep quality.

    Time frame: 1 Day

  5. Subjective Sleep Latency Night 3

    Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline

    Time frame: 1 Day

  6. Subjective Wake After Sleep Onset Night 3

    Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline

    Time frame: 1 Day

  7. Karolinska Sleepiness Scale Day 4

    Self-reported fatigue measure analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight. The KSS is a single question asking the subject to rate how sleepy they feel at that moment on a 9-point scale where 1 = extremely awake and 9 = extremely sleepy/fighting to stay wake.

    Time frame: 1 Day

07

Results

Posted Nov 3, 2021

Participant flow

Participant flow — Overall Study
MilestoneTasimelteonPlacebo
Started1312
Completed1312
Not completed00

Outcome measures

PrimaryTotal Sleep Time in the First Two-Thirds of the Night on the Night(s) Most Likely to be Disrupted

Measured using polysomnography (PSG) and analyzed as change from baseline. Examination of the observational phase baseline data demonstrated that Night 3 was the night most disrupted.

Time frame:
4 days
Reported as:
Least squares mean · minutes
Total Sleep Time in the First Two-Thirds of the Night on the Night(s) Most Likely to be Disrupted
minutesTasimelteonPlacebo
Total Sleep Time in the First Two-Thirds of the Night on the Night(s) Most Likely to be Disrupted76.2 ± 11.21341.4 ± 11.882
Statistical analysis
  • Tasimelteon vs Placebo · ANCOVA · p = 0.0354 · Mean difference (net): 34.75
SecondaryPatient Global Impression of Severity (PGI-S) Day 4

Self-reported global index measure analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight. The PGI-S is a single question asking the subject to rate their jet-lag condition at the present time on a scale of 1 "Normal" to 4 "Severe".

Time frame:
1 Day
Reported as:
Least squares mean · units on a scale
Patient Global Impression of Severity (PGI-S) Day 4
units on a scaleTasimelteonPlacebo
Patient Global Impression of Severity (PGI-S) Day 4-0.71 ± 0.174-0.07 ± 0.183
Statistical analysis
  • Tasimelteon vs Placebo · ANCOVA · p = 0.0168 · Mean difference (net): -0.63
SecondaryTotal Sleep Time in the First Two-Thirds of the Night (All 3 Nights)

Measured using polysomnography (PSG) and analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight.

Time frame:
3 Days
Reported as:
Least squares mean · Minutes
Total Sleep Time in the First Two-Thirds of the Night (All 3 Nights)
MinutesTasimelteonPlacebo
Total Sleep Time in the First Two-Thirds of the Night (All 3 Nights)131.4 ± 35.24340.9 ± 37.774
Statistical analysis
  • Tasimelteon vs Placebo · ANCOVA · p = 0.0785 · Mean difference (net): 90.56
SecondarySubjective Total Sleep Time on Night 3

Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline

Time frame:
1 Day
Reported as:
Least squares mean · Minutes
Subjective Total Sleep Time on Night 3
MinutesTasimelteonPlacebo
Subjective Total Sleep Time on Night 3111.9 ± 23.01233.47 ± 24.555
Statistical analysis
  • Tasimelteon vs Placebo · ANCOVA · p = 0.0225 · Mean difference (net): 78.45
SecondarySubjective Sleep Quality Night 3

Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline. Sleep quality was ranked from 1 "Poor" to 5 "Excellent" and was the subscale of the post-sleep questionnaire used to determine subjective sleep quality.

Time frame:
1 Day
Reported as:
Least squares mean · units on a scale
Subjective Sleep Quality Night 3
units on a scaleTasimelteonPlacebo
Subjective Sleep Quality Night 31.31 ± 0.2730.36 ± 0.290
Statistical analysis
  • Tasimelteon vs Placebo · ANCOVA · p = 0.0198 · Mean difference (net): 0.95
SecondarySubjective Sleep Latency Night 3

Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline

Time frame:
1 Day
Reported as:
Least squares mean · Minutes
Subjective Sleep Latency Night 3
MinutesTasimelteonPlacebo
Subjective Sleep Latency Night 3-20.6 ± 8.396.0 ± 8.76
Statistical analysis
  • Tasimelteon vs Placebo · ANCOVA · p = 0.0347 · Mean difference (net): -26.55
SecondarySubjective Wake After Sleep Onset Night 3

Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline

Time frame:
1 Day
Reported as:
Least squares mean · Minutes
Subjective Wake After Sleep Onset Night 3
MinutesTasimelteonPlacebo
Subjective Wake After Sleep Onset Night 3-81.1 ± 22.53-24.7 ± 24.01
Statistical analysis
  • Tasimelteon vs Placebo · ANCOVA · p = 0.0840 · Mean difference (net): -56.44
SecondaryKarolinska Sleepiness Scale Day 4

Self-reported fatigue measure analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight. The KSS is a single question asking the subject to rate how sleepy they feel at that moment on a 9-point scale where 1 = extremely awake and 9 = extremely sleepy/fighting to stay wake.

Time frame:
1 Day
Reported as:
Least squares mean · units on a scale
Karolinska Sleepiness Scale Day 4
units on a scaleTasimelteonPlacebo
Karolinska Sleepiness Scale Day 4-1.69 ± 0.388-0.69 ± 0.409
Statistical analysis
  • Tasimelteon vs Placebo · ANCOVA · p = 0.0765 · Mean difference (net): -1.00

Adverse events

Collected over 15 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tasimelteon0/13 (0%)0/13 (0%)7/13 (53.8%)
Placebo0/12 (0%)0/12 (0%)4/12 (33.3%)
Most frequent other events
Most frequent other events
EventTasimelteonPlacebo
HeadacheNervous system disorders4/134/12
VomitingGastrointestinal disorders2/130/12
NauseaGastrointestinal disorders0/131/12
MalaiseGeneral disorders0/131/12
NasopharyngitisInfections and infestations0/131/12
DehydrationMetabolism and nutrition disorders0/131/12
Skin irritationSkin and subcutaneous tissue disorders0/131/12
Ear discomfortEar and labyrinth disorders1/130/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)TasimelteonPlaceboTotal
Mean51.3 ± 13.4748.2 ± 16.0649.8 ± 14.54
Sex: Female, Male
Sex: Female, Male(Participants)TasimelteonPlaceboTotal
Female9615
Male4610
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TasimelteonPlaceboTotal
Hispanic or Latino101
Not Hispanic or Latino121224
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TasimelteonPlaceboTotal
American Indian or Alaska Native000
Asian235
Native Hawaiian or Other Pacific Islander000
Black or African American134
White10616
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)TasimelteonPlaceboTotal
United States131225
08

Study locations

3 sites
  • Vanda Investigational Site
    Alameda, California 94501, United States
  • Vanda Investigational Site
    Santa Monica, California 90404, United States
  • Vanda Investigational Site
    Chevy Chase, Maryland 20815, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Nov 2017, 16 months.

Results were first posted in Nov 2021, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2016
First posted
Sep 25, 2017
StartActual
Jul 2016
Primary completionActual
Nov 2017
CompletionActual
Nov 2017
Results first posted
Nov 3, 2021
Last update
Nov 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03291041
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Jul 2016
Primary completion
Nov 2017
Completion
Nov 2017
Results posted
Nov 3, 2021
Last update
Nov 3, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion